BioCentury
ARTICLE | Clinical News

Budesonide rectal foam regulatory update

February 3, 2014 8:00 AM UTC

Salix said FDA accepted for review an NDA for budesonide 2 mg rectal foam for induction of remission in patients with active mild to moderate ulcerative colitis (UC) extending up to 40 cm from the ana...